Module 10: Diabetes/Insulin (b) Flashcards
Insulin in T2DM
- Indications for Unstable T2DM
-Insulin need may NOT be permanent
—High A1C (>8.5%, and definitely >10%)
—Fasting plasma glucose >250 mg/dL
—Random glucose >300 mg/dL - Primary A/E — Hypoglycemia & Weight gain
Basal Analogues Insulin
-Info — Lantus & Levemir
- CANNOT be mixed in syringe w/ other insulin
2. 24-hr insulin’s — can be dosed q12 hrs (esp Levemir)
Initiating Insulin Therapy
- Start at 10 units per day — Or initial dose is 0.1-0.2 units/kg/day
- Decrease dose by about 20% if hypoglycemia — 40% decrease if severe hypoglycemia, such as BG <40
Basal Insulin + GLP-1 RA?
1.Combined effect is to decrease both fasting blood glucose and postprandial glucose excursions
- Insulin will increase body weight and has relatively high hypoglycemia risk
- GLP-1 RA will decrease body weight and has a low hypoglycemia risk
Intensifying Insulin for T2DM
- If Basal insulin + GLP-1 RA is NOT working, rapid-acting prandial insulin can be added
- Start with only 1 meal coverage, not all 3 — Ex: 4 units w/ meal (or no more than 10% of basal dose)
Pre-Mixed Insulin Therapy for T2DM
-70/30 or 75/25
- Administer TWICE daily w/ meals — Before breakfast and evening meal
Intensive Insulin Therapy
-Multiple Daily Injections/Basal-Bolus Reg
- Basal insulin PLUS Rapid-acting insulin w/ all meals
2. REFER to endocrinologist
Inhaled Insulin
-Afrezza
- Dry powder formulation of RAPID-ACTING insulin
- Many patients still need to inject long-acting insulin
- Indicated for use in adults >18 years — NOT for children or pregnancy
- CONTRAINDICATED in patients w/ chronic lung disease, such as ASTHMA or COPD **TEST — NOT for Smoking or Lung cancer
- MONITORING — Pulmonary function testing w/ Spirometry **TEST
- Monitor baseline, 6 moths, and annually thereafter
PULMONARY TOXICITY**
Sx’s of Hypoglycemia
- Mild Hypoglycemia 50-70 mg/dL — palpitations, tremor, Humber, sweating, anxiety, paresthesia
- Moderate Hypoglycemia 50-70 mg/dL — behavioral changes, emotional lability, difficulty thinking, confusion
- Severe hypoglycemia <50 mg/dL — Severe confusion, unconsciousness, seizure, coma, death — Requires help from another individual
Factors that Increase risk of Hypoglycemia
- Impaired Renal or hepatic function
- Longer duration of DM
- Frailty and older age
- Cognitive impairment
- Impaired counter-regulatory response, hypoglycemia unawareness
- Physical or intellectual disability
- ETOH
- Poly-pharmacy — especially ACEi, ARB, Non-selective BB
Combination Therapy
-Do NOT combine?
- NEVER COMBINE
- DPP-4 inhibitor and GLP-1agonist
- Meglitinides and Sulfonylurea’s
Combination Therapy
-Combinations w/ Cautions Sulfonylurea + Basal Insulin
- Sulfonylurea + Basal Insulin
- Discontinuing sulfonylurea is often recommended w/ insulin use - This combo leads to
- HIGH glucose lowering
- HIEST RISK for hypoglycemia — Additive effects
- WEIGHT GAIN -Additive effects
- Variable cost
Combination Therapy
-Combinations w/ Caution TZD + Basal Insulin
- HIGH glucose lowering
- HIGH RISK for hypoglycemia
- Weight gain — additive effects
- Edema — additive effects
- Variable cost
T2DM and CVD Considerations
- The following options have CV even risk reduction
- SGLT-2i’s — “flozin’s”
- GLP-1 RAs — “glutide”
General Considerations for DM and other systems?
- Albuminuria — Consider ACE or ARB
- HTN? — Consider ACE or ARB PLUS CCB and/or thiazide as needed
- Dyslipidemia — Statin — Consider ASCVD risk calculation